Developer docs
API playgroundTry for free, no card

Search company profiles

Alithea Genomics

Full company profile

uuid0002f2o

Namestring
Alithea Genomics
Legal namestring
Alithea Genomics SA
Company typeenum
Private
Founded yearint
2020
Descriptiontext

Alithea Genomics is a privately held Swiss biotechnology company, founded in 2020 as an EPFL spin-off and headquartered in Epalinges (Lausanne area), with a wholly-owned US subsidiary in Frederick, Maryland. The company develops and commercializes the MERCURIUS™ platform family of massively multiplexed RNA-sequencing library preparation technologies, comprising three core product lines — MERCURIUS™ DRUG-seq (extraction-free bulk RNA-seq directly from cells or spheroids in 96-, 384-, and 1536-well formats), MERCURIUS™ BRB-seq (multiplexed bulk RNA-seq for purified RNA across human, blood, and plant samples), and MERCURIUS™ FLASH-seq (plate-based, full-length single-cell RNA-seq). The platforms use early plate-based sample barcoding to pool up to 384 (and now 1,536) samples into a single library preparation tube, reducing plastic consumable use by up to 95% and enabling transcriptome-wide profiling at screening scale with detection of 12,000–15,000 genes per sample at shallow sequencing depths (0.7M–5M reads).

The company operates a dual revenue model selling kits (one-time product revenue) and corresponding sequencing services (outsourced processing) to pharmaceutical, biotechnology, CRO, toxicology, agrochemical, cosmetics, and academic research customers. Named enterprise adopters include Roche, Bayer, Novo Nordisk, Johnson & Johnson, Syngenta, Axxam, the Broad Institute, Karolinska Institutet, Ludwig Cancer Research, Massachusetts General Hospital / Harvard Medical School, bit.bio, CNRS, the University of Pennsylvania, A*STAR, the University of Lausanne, and the Institute of Molecular Biology, alongside 100+ labs worldwide and 50+ publications powered by the technology. Distribution is hybrid: direct enterprise sales (led by co-founder and CCO Riccardo Dainese) layered with a June 2026 global distribution agreement with Revvity Inc. for DRUG-seq and Total DRUG-seq, plus regional distributors Dakewe (China) and Funakoshi (Japan).

Alithea is venture-backed, having raised approximately CHF 10.7M (~$11.5M) in cumulative disclosed funding across seed rounds in 2022, 2024, and 2026, with Genku Ventures, Novalis Biotech, Zürcher Kantonalbank, TechU Ventures, and the Swiss Technology Fund among its backers. The company holds ISO 9001:2015 certification, is a technology partner in the OASIS Consortium for Next Generation Risk Assessment led by HESI and the Broad Institute, and integrates its chemistries with SPT Labtech's firefly liquid handling platform. Leadership transitioned in March 2026 with Frederik Decouttere assuming the CEO role and Dainese moving to CCO to anchor the company's commercial expansion phase.

Short descriptiontext

Alithea Genomics is a Swiss EPFL spin-off that develops MERCURIUS multiplexed RNA-sequencing library prep kits and services, serving pharmaceutical, biotech, CRO, toxicology, agrochemical, and academic research customers with screening-scale transcriptome profiling at reduced cost and hands-on time.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersEpalinges, Switzerland
HQ citystring
Epalinges
HQ countrystring
Switzerland
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
RNA sequencing kits, transcriptomics services, library preparation kits, single-cell RNA sequencing, drug discovery screening
Industry4 codes
PRIMARYHLAGANAE
Transcriptomics & Gene Expression Profiling Services
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Specialty Lab Services (Genomics/Proteomics/Cellomics)
SECONDARYHLAGAJAD
Bioinformatics & Multi-omics Analysis Software
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAGAIAF
Molecular Biology & Genomics Instruments (PCR/qPCR, Sequencing, Microarrays)
SECONDARYHLAGANAI
Bioinformatics, Multi-Omics Data Analysis & Interpretation Services
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Specialty Lab Services (Genomics/Proteomics/Cellomics)
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • In-Vitro Diagnostic Substance Manufacturing325413
SIC code2 codes
  • Services-Medical Laboratories8071
  • In Vitro & In Vivo Diagnostic Substances2835
Product category
Genomics Research Tools
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model3 records
1RNA-seq Kits Sales
TypeOne Time License
Description

Alithea Genomics sells its MERCURIUS™ kit portfolio (DRUG-seq, BRB-seq, FLASH-seq, and variants) directly to pharmaceutical, biotech, CRO, academic, and agritech/cosmetics customers. Kits are sold in multiple formats (96-well, 384-well, 1536-well) targeting cell lysate, purified RNA, spheroid, blood, and single-cell inputs. The company also sells accessories (UDI expansion modules, lysis modules) as add-on products.

alitheagenomics.com
2RNA-seq Services
TypeProfessional Services
Description

Alithea Genomics provides transcriptomics services using its MERCURIUS™ technology platforms, enabling customers who prefer outsourced processing to access DRUG-seq, BRB-seq, FLASH-seq, and related services without purchasing kits. Services are offered for the same sample types covered by the kit portfolio.

alitheagenomics.com
3Proprietary Transcriptomic Data Assets
TypeData Monetisation
Description

The company plans to build proprietary transcriptomic data assets for AI/ML initiatives, suggesting a potential future data monetization stream. The company has profiled over 1 million full transcriptomes and has access to large-scale compound-response datasets.

finsmes.com
Marketing channels10 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels5 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Technology or R&D, Supply Chain, Operations, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 7 records shown
1MERCURIUS
Description

Proprietary technology platform family including DRUG-seq, BRB-seq, and FLASH-seq for scalable RNA sequencing solutions.

alitheagenomics.com
+6 more records
Core offering1 text field

Alithea Genomics develops and commercializes the proprietary MERCURIUS™ platform of RNA sequencing kits and matched services for high-throughput, screening-scale transcriptomics. Its products use early plate-based sample barcoding and massively multiplexed library preparation (pooling up to 384, or up to 1,536, samples per tube) combined with extraction-free workflows to deliver 3′ mRNA, full-length, total RNA, and single-cell readouts for pharmaceutical, biotech, CRO, agritech, cosmetics, and academic customers.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 6 values shown
  • Up to 384 samples pooled and processed in a single tube, reducing plastic consumable use by up to 95%
+5 more records
Product overview1 text field

Alithea Genomics offers a modular platform of RNA sequencing products organized around three core technology families: MERCURIUS DRUG-seq (extraction-free workflows for cells and spheroids), MERCURIUS BRB-seq (for purified RNA samples), and MERCURIUS FLASH-seq (for single-cell and low-input applications). Each technology family includes multiple kit variants differentiated by RNA coverage (3′ mRNA-seq vs. full-length/total RNA-seq), sample type compatibility, and throughput level. The DRUG-seq family encompasses standard 384-well kits, Total DRUG-seq (full-length), Spheroid DRUG-seq (for 3D models), and 1536 DRUG-seq (ultra-high-throughput). The BRB-seq family includes standard, Total, Full-Length, Low-Input FLASH, High-Sensitivity, Plant, and Blood variants. FLASH-seq covers single-cell and low-input applications. Corresponding service offerings mirror all kit products, enabling customers to access the technology via outsourced sequencing services. The company also provides ISO 9001:2015 certified products.

Product and service23 records
1MERCURIUS™ DRUG-seq Kit
CategoryRNA Sequencing Kit
Description

Extraction-free 3′ mRNA library preparation kit that performs bulk RNA-seq directly on cells in 96- or 384-well plates without RNA isolation, enabling high-throughput compound screening and drug discovery transcriptomics.

2MERCURIUS™ Total DRUG-seq Kit
CategoryRNA Sequencing Kit
Description

Extraction-free total RNA-seq kit providing full-length transcriptome coverage including lncRNAs and non-coding RNAs for large-scale compound screens, toxicology studies, and target validation in 96- and 384-well formats.

3MERCURIUS™ Spheroid DRUG-seq Kit
CategoryRNA Sequencing Kit
Description

Extraction-free RNA-seq kit for 3D spheroid and organoid models with optimized lysis buffer, enabling high-throughput transcriptomic profiling in physiologically relevant drug screening and toxicity models.

4MERCURIUS™ 1536 DRUG-seq Kit
CategoryRNA Sequencing Kit
Description

Ultra-high-throughput 3′ mRNA-seq kit enabling transcriptome-wide profiling directly from 1536-well assay plates for screening-scale compound-response data and AI-ready perturbation datasets.

5MERCURIUS™ BRB-seq Kit
CategoryRNA Sequencing Kit
Description

Massively multiplexed 3′ bulk RNA-seq kit for purified RNA from eukaryotic cells, designed for large cohorts and multi-condition gene expression studies with early sample barcoding.

6MERCURIUS™ Total BRB-seq Kit
CategoryRNA Sequencing Kit
Description

Total RNA BRB-seq kit capturing coding and non-coding transcripts for scalable whole-transcriptome profiling from purified RNA samples.

7MERCURIUS™ Full-Length BRB-seq Kit
CategoryRNA Sequencing Kit
Description

Multiplexed full-length mRNA-seq kit for purified RNA enabling splicing, isoform, and expression analysis across many samples.

8MERCURIUS™ Low-Input FLASH-seq Kit
CategoryRNA Sequencing Kit
Description

Ultra-sensitive full-length RNA-seq kit for low-input RNA samples ranging from picogram to nanogram amounts.

9MERCURIUS™ High-Sensitivity BRB-seq Kit
CategoryRNA Sequencing Kit
Description

High-sensitivity BRB-seq kit for transcriptomics projects with limited input RNA starting from 100 pg per sample.

10MERCURIUS™ Total Blood BRB-seq Kit
CategoryRNA Sequencing Kit
Description

Total RNA BRB-seq kit for scalable total RNA-seq from purified blood RNA, enabling maximum detection of coding and non-coding transcripts for industrial and academic clients.

11MERCURIUS™ Plant BRB-seq Kit
CategoryRNA Sequencing Kit
Description

BRB-seq kit tailored for plant RNA samples, enabling scalable multiplexed RNA sequencing for plant research applications.

12MERCURIUS™ FLASH-seq (Single-Cell) Kit
CategoryRNA Sequencing Kit
Description

Plate-based full-length single-cell RNA-seq kit delivering ultra-sensitive detection of rare cells with automation-friendly workflows, capturing up to 2x more genes than competing single-cell solutions.

13DRUG-seq Service
CategoryRNA Sequencing Service
Description

Fee-for-service extraction-free RNA-seq using MERCURIUS DRUG-seq chemistry for adherent and suspension cell lines, targeting screening, mechanism-of-action studies, and toxicity profiling at scale.

14Total DRUG-seq Service
CategoryRNA Sequencing Service
Description

Fee-for-service extraction-free total RNA-seq using MERCURIUS Total DRUG-seq for large-scale compound and toxicology screens requiring whole-transcriptome readouts.

15Single-Cell FLASH-seq Service
CategoryRNA Sequencing Service
Description

Fee-for-service plate-based full-length single-cell RNA-seq using MERCURIUS FLASH-seq for sorted or rare cells, delivering ultra-sensitive transcriptomes.

16Spheroid DRUG-seq Service
CategoryRNA Sequencing Service
Description

Fee-for-service extraction-free RNA-seq for 3D spheroid models capturing complex biology, mechanisms, and toxicity responses in physiologically relevant models.

17BRB-seq Service
CategoryRNA Sequencing Service
Description

Fee-for-service multiplexed bulk RNA-seq for purified RNA, ideal for cohorts, time-courses, and large gene expression profiling projects.

18Total BRB-seq Service
CategoryRNA Sequencing Service
Description

Fee-for-service total RNA BRB-seq capturing coding and non-coding transcripts for scalable whole-transcriptome studies on purified RNA samples.

19Full-Length BRB-seq Service
CategoryRNA Sequencing Service
Description

Fee-for-service full-length mRNA BRB-seq for isoform, splicing, and expression analyses across many purified RNA samples.

20Low-Input FLASH-seq Service
CategoryRNA Sequencing Service
Description

Fee-for-service full-length RNA-seq for scarce or precious low-input RNA providing high sensitivity from picogram to nanogram inputs.

21High-Sensitivity BRB-seq Service
CategoryRNA Sequencing Service
Description

Fee-for-service high-sensitivity BRB-seq for transcriptomics projects with limited input RNA starting from 100 pg per sample.

22Total Blood BRB-seq Service
CategoryRNA Sequencing Service
Description

Fee-for-service total RNA-seq from purified blood RNA for maximum detection of coding and non-coding transcripts.

23Plant BRB-seq Service
CategoryRNA Sequencing Service
Description

Fee-for-service BRB-seq tailored for plant RNA samples, enabling scalable multiplexed RNA sequencing for plant research.

Scale indicator10 records

Each record includes

Type, Value, Description, Source

Partnership6 partners
Strategic tierFlagship / StrategicTypeChannel Partner/ Reseller/ DistributorAnnounced on2026-06-08
Description

Revvity Inc. serves as the global commercial distributor for MERCURIUS™ DRUG-seq and MERCURIUS™ Total DRUG-seq solutions. The distribution agreement leverages Revvity's comprehensive drug discovery and screening portfolio and global commercial network to broaden access to Alithea's transcriptomics technologies. The collaboration enables researchers to integrate transcriptomic profiling into Revvity's large-scale phenotypic and functional genomics workflows. Revvity had 2025 revenue of $2.9B with ~11,000 employees serving customers in 160+ countries.

Strategic tierCore / StrategicTypeTechnology or IntegrationAnnounced on2025-11-05
Description

SPT Labtech and Alithea Genomics announced a collaboration to develop automation solutions for single-cell transcriptomics. The partnership integrates Alithea's MERCURIUS™ FLASH-seq and MERCURIUS™ Total DRUG-seq technologies with SPT Labtech's firefly® liquid handling platform for automated, scalable, and reproducible RNA-seq workflows. The companies released joint application notes and hosted a co-marketing webinar on November 10, 2025. This addresses the key bottleneck of manual library preparation in single-cell transcriptomics, improving reproducibility, throughput, and accessibility.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2023-01-17
Description

PamGene International is a partner in the MAINLINE consortium with Alithea Genomics and Lausanne University Hospital, awarded a €1M Eurostars grant to develop a pan-cancer blood test for predicting immune checkpoint inhibitor (ICI) therapy response. The project combines transcriptomics (Alithea's technology) and kinomic profiling (PamGene's technology) to create a multi-omics biomarker model validated in clinical settings.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2023-01-17
Description

Lausanne University Hospital (CHUV) is a partner in the MAINLINE consortium with Alithea Genomics and PamGene International, awarded a €1M Eurostars grant. CHUV contributes clinical expertise and validation capabilities for the pan-cancer blood test project, combining transcriptomic and kinomic biomarker profiles to predict ICI therapy response across multiple cancers.

Strategic tierCore / StrategicTypeStrategic or Co-development Partner
Description

Arctoris partnered with Alithea Genomics for the 1536 DRUG-seq early access launch webinar (June 24, 2026). Arctoris contributes its Ulysses® automated platform for fully automated experimental execution in 1536-well format, including cell preparation, compound treatment, incubation, and sample preparation. The partnership demonstrates how automated workflows enable reproducible 1536-well transcriptomic screening and bridges technical feasibility with practical drug discovery application.

Strategic tierCore / StrategicTypeStrategic or Co-development Partner
Description

Alithea Genomics is a technology partner in the OASIS Consortium (Omics for Assessing Signatures for Integrated Safety), a global initiative launched in 2023 led by HESI Global and The Broad Institute with 60+ global partners. The consortium evaluates multi-omics technologies including transcriptomics, proteomics, and Cell Painting for predictive chemical safety assessment. Alithea provides MERCURIUS™ DRUG-seq as the transcriptomic technology platform. The consortium aims to build confidence in Next Generation Risk Assessment (NGRA) frameworks and reduce reliance on animal testing.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Lexogen offers a portfolio of RNA-seq library prep kits (QuantSeq, CORALL, SIRV spike-ins) targeting similar pharma/biotech and academic customers. It is the closest direct competitor in terms of product category (RNA-seq kits) and customer base (transcriptomics researchers).

TypeDirect peer
Description

10x Genomics' Chromium single-cell RNA-seq platform competes directly with Alithea's FLASH-seq offering and serves overlapping pharma/biotech and academic customers. Both companies target the high-throughput transcriptomics market with differentiated single-cell workflows.

TypeDirect peer
Description

Parse Biosciences offers Evercode single-cell RNA-seq kits that compete with FLASH-seq for fixed-cell and high-throughput single-cell applications. Both target pharma/biotech and academic researchers needing scalable, plate-based scRNA-seq.

TypeDirect peer
Description

Bio-Rad's ddSEQ single-cell RNA-seq and Droplet Digital PCR products overlap with Alithea's FLASH-seq and BRB-seq offerings. Both serve drug discovery and translational research customers with high-throughput molecular biology tools.

TypeEmerging player
Description

Fluent BioSciences offers PIPseq single-cell RNA-seq technology targeting similar translational and pharma customers. It is a smaller emerging competitor in the plate-based single-cell space where Alithea's FLASH-seq also competes.

TypeBroad incumbent
Description

Illumina dominates the sequencing-instrument market and also sells its own library prep and bulk RNA-seq reagents (e.g., TruSeq, Illumina Stranded mRNA). Alithea's kits are compatible with Illumina sequencers but compete with Illumina's reagent catalog for the same pharma/biotech budget.

TypeBroad incumbent
Description

NEB offers a broad portfolio of RNA-seq library prep reagents (NEBNext) that compete with MERCURIUS kits across academic and translational customers. As a large, established enzyme/reagent vendor, NEB represents a broad incumbent alternative.

8Takara Bio
TypeBroad incumbent
Description

Takara Bio provides NGS library prep kits (SMARTer, ThruPLEX) and single-cell reagents overlapping with Alithea's BRB-seq and FLASH-seq offerings. As a diversified Japanese life sciences tools provider, it is a comparable broad incumbent.

TypeBroad incumbent
Description

Revvity is Alithea's global distribution partner and a major life sciences tools player (formerly PerkinElmer) serving pharma, biotech, and diagnostics customers. While now a commercial partner, Revvity also offers overlapping drug-discovery and screening products in adjacent categories.

TypeEmerging player
Description

Element Biosciences' AVITI sequencer is compatible with Alithea's MERCURIUS kits and competes in the broader NGS ecosystem. While Element focuses on sequencing instruments rather than library prep, the two companies share an emerging-player positioning around democratizing NGS for pharma and academic customers.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers20 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration1 record

Each record includes

Title, Type, Description, Source

AI capability3 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature9 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles5 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds8 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors8 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Alithea Genomics

Genomics Research Toolsalitheagenomics.com

Alithea Genomics is a Swiss EPFL spin-off that develops MERCURIUS multiplexed RNA-sequencing library prep kits and services, serving pharmaceutical, biotech, CRO, toxicology, agrochemical, and academic research customers with screening-scale transcriptome profiling at reduced cost and hands-on time.

What Alithea Genomics does

Alithea Genomics is a privately held Swiss biotechnology company, founded in 2020 as an EPFL spin-off and headquartered in Epalinges (Lausanne area), with a wholly-owned US subsidiary in Frederick, Maryland. The company develops and commercializes the MERCURIUS™ platform family of massively multiplexed RNA-sequencing library preparation technologies, comprising three core product lines — MERCURIUS™ DRUG-seq (extraction-free bulk RNA-seq directly from cells or spheroids in 96-, 384-, and 1536-well formats), MERCURIUS™ BRB-seq (multiplexed bulk RNA-seq for purified RNA across human, blood, and plant samples), and MERCURIUS™ FLASH-seq (plate-based, full-length single-cell RNA-seq). The platforms use early plate-based sample barcoding to pool up to 384 (and now 1,536) samples into a single library preparation tube, reducing plastic consumable use by up to 95% and enabling transcriptome-wide profiling at screening scale with detection of 12,000–15,000 genes per sample at shallow sequencing depths (0.7M–5M reads).

The company operates a dual revenue model selling kits (one-time product revenue) and corresponding sequencing services (outsourced processing) to pharmaceutical, biotechnology, CRO, toxicology, agrochemical, cosmetics, and academic research customers. Named enterprise adopters include Roche, Bayer, Novo Nordisk, Johnson & Johnson, Syngenta, Axxam, the Broad Institute, Karolinska Institutet, Ludwig Cancer Research, Massachusetts General Hospital / Harvard Medical School, bit.bio, CNRS, the University of Pennsylvania, A*STAR, the University of Lausanne, and the Institute of Molecular Biology, alongside 100+ labs worldwide and 50+ publications powered by the technology. Distribution is hybrid: direct enterprise sales (led by co-founder and CCO Riccardo Dainese) layered with a June 2026 global distribution agreement with Revvity Inc. for DRUG-seq and Total DRUG-seq, plus regional distributors Dakewe (China) and Funakoshi (Japan).

Alithea is venture-backed, having raised approximately CHF 10.7M (~$11.5M) in cumulative disclosed funding across seed rounds in 2022, 2024, and 2026, with Genku Ventures, Novalis Biotech, Zürcher Kantonalbank, TechU Ventures, and the Swiss Technology Fund among its backers. The company holds ISO 9001:2015 certification, is a technology partner in the OASIS Consortium for Next Generation Risk Assessment led by HESI and the Broad Institute, and integrates its chemistries with SPT Labtech's firefly liquid handling platform. Leadership transitioned in March 2026 with Frederik Decouttere assuming the CEO role and Dainese moving to CCO to anchor the company's commercial expansion phase.

Alithea Genomics firmographics

Firmographics
Name
Alithea Genomics
Legal name
Alithea Genomics SA
Website
https://alitheagenomics.com
Company type
Private
Founded year
2020
Operating status
Operating
Headcount range
11–50 employees
Short description
Alithea Genomics is a Swiss EPFL spin-off that develops MERCURIUS multiplexed RNA-sequencing library prep kits and services, serving pharmaceutical, biotech, CRO, toxicology, agrochemical, and academic research customers with screening-scale transcriptome profiling at reduced cost and hands-on time.
Ownership category
akta.pro rank

Alithea Genomics industry classification

Industry
Product category
Genomics Research Tools
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), In-Vitro Diagnostic Substance Manufacturing (325413)
SIC
Services-Medical Laboratories (8071), In Vitro & In Vivo Diagnostic Substances (2835)
akta.pro industry
PRIMARYHLAGANAE
Transcriptomics & Gene Expression Profiling Services
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Specialty Lab Services (Genomics/Proteomics/Cellomics)
SECONDARYHLAGAJAD
Bioinformatics & Multi-omics Analysis Software
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAGAIAF
Molecular Biology & Genomics Instruments (PCR/qPCR, Sequencing, Microarrays)
SECONDARYHLAGANAI
Bioinformatics, Multi-Omics Data Analysis & Interpretation Services
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Specialty Lab Services (Genomics/Proteomics/Cellomics)

Keywords

  • RNA sequencing kits
  • Transcriptomics services
  • Library preparation kits
  • Single-cell RNA sequencing
  • Drug discovery screening

Where Alithea Genomics is headquartered

Location

Headquarters

HQ city
Epalinges
HQ country
Switzerland
HQ region
Europe

Offices2 records

Markets served

Alithea Genomics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Supply Chain, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. RNA-seq Kits Sales: Alithea Genomics sells its MERCURIUS™ kit portfolio (DRUG-seq, BRB-seq, FLASH-seq, and variants) directly to pharmaceutical, biotech, CRO, academic, and agritech/cosmetics customers. Kits are sold in multiple formats (96-well, 384-well, 1536-well) targeting cell lysate, purified RNA, spheroid, blood, and single-cell inputs. The company also sells accessories (UDI expansion modules, lysis modules) as add-on products.
  2. RNA-seq Services: Alithea Genomics provides transcriptomics services using its MERCURIUS™ technology platforms, enabling customers who prefer outsourced processing to access DRUG-seq, BRB-seq, FLASH-seq, and related services without purchasing kits. Services are offered for the same sample types covered by the kit portfolio.
  3. Proprietary Transcriptomic Data Assets: The company plans to build proprietary transcriptomic data assets for AI/ML initiatives, suggesting a potential future data monetization stream. The company has profiled over 1 million full transcriptomes and has access to large-scale compound-response datasets.

Go-to-market motion1 record

Distribution channels5 records

Marketing channels10 records

Alithea Genomics product offering

Product offering

Core offering

Alithea Genomics develops and commercializes the proprietary MERCURIUS™ platform of RNA sequencing kits and matched services for high-throughput, screening-scale transcriptomics. Its products use early plate-based sample barcoding and massively multiplexed library preparation (pooling up to 384, or up to 1,536, samples per tube) combined with extraction-free workflows to deliver 3′ mRNA, full-length, total RNA, and single-cell readouts for pharmaceutical, biotech, CRO, agritech, cosmetics, and academic customers.

Product overview

Alithea Genomics offers a modular platform of RNA sequencing products organized around three core technology families: MERCURIUS DRUG-seq (extraction-free workflows for cells and spheroids), MERCURIUS BRB-seq (for purified RNA samples), and MERCURIUS FLASH-seq (for single-cell and low-input applications). Each technology family includes multiple kit variants differentiated by RNA coverage (3′ mRNA-seq vs. full-length/total RNA-seq), sample type compatibility, and throughput level. The DRUG-seq family encompasses standard 384-well kits, Total DRUG-seq (full-length), Spheroid DRUG-seq (for 3D models), and 1536 DRUG-seq (ultra-high-throughput). The BRB-seq family includes standard, Total, Full-Length, Low-Input FLASH, High-Sensitivity, Plant, and Blood variants. FLASH-seq covers single-cell and low-input applications. Corresponding service offerings mirror all kit products, enabling customers to access the technology via outsourced sequencing services. The company also provides ISO 9001:2015 certified products.

Differentiator

Problem solved

Functional benefit

Brands

  • MERCURIUS: Proprietary technology platform family including DRUG-seq, BRB-seq, and FLASH-seq for scalable RNA sequencing solutions.
  • MERCURIUS 1536 DRUG-seq
  • MERCURIUS FLASH-seq
  • MERCURIUS Total DRUG-seq
  • MERCURIUS Spheroid DRUG-seq
  • MERCURIUS BRB-seq
  • MERCURIUS DRUG-seq

Products and services

  • MERCURIUS™ DRUG-seq Kit Extraction-free 3′ mRNA library preparation kit that performs bulk RNA-seq directly on cells in 96- or 384-well plates without RNA isolation, enabling high-throughput compound screening and drug discovery transcriptomics.
  • MERCURIUS™ Total DRUG-seq Kit Extraction-free total RNA-seq kit providing full-length transcriptome coverage including lncRNAs and non-coding RNAs for large-scale compound screens, toxicology studies, and target validation in 96- and 384-well formats.
  • MERCURIUS™ Spheroid DRUG-seq Kit Extraction-free RNA-seq kit for 3D spheroid and organoid models with optimized lysis buffer, enabling high-throughput transcriptomic profiling in physiologically relevant drug screening and toxicity models.
  • MERCURIUS™ 1536 DRUG-seq Kit Ultra-high-throughput 3′ mRNA-seq kit enabling transcriptome-wide profiling directly from 1536-well assay plates for screening-scale compound-response data and AI-ready perturbation datasets.
  • MERCURIUS™ BRB-seq Kit Massively multiplexed 3′ bulk RNA-seq kit for purified RNA from eukaryotic cells, designed for large cohorts and multi-condition gene expression studies with early sample barcoding.
  • MERCURIUS™ Total BRB-seq Kit Total RNA BRB-seq kit capturing coding and non-coding transcripts for scalable whole-transcriptome profiling from purified RNA samples.
  • MERCURIUS™ Full-Length BRB-seq Kit Multiplexed full-length mRNA-seq kit for purified RNA enabling splicing, isoform, and expression analysis across many samples.
  • MERCURIUS™ Low-Input FLASH-seq Kit Ultra-sensitive full-length RNA-seq kit for low-input RNA samples ranging from picogram to nanogram amounts.
  • MERCURIUS™ High-Sensitivity BRB-seq Kit High-sensitivity BRB-seq kit for transcriptomics projects with limited input RNA starting from 100 pg per sample.
  • MERCURIUS™ Total Blood BRB-seq Kit Total RNA BRB-seq kit for scalable total RNA-seq from purified blood RNA, enabling maximum detection of coding and non-coding transcripts for industrial and academic clients.
  • MERCURIUS™ Plant BRB-seq Kit BRB-seq kit tailored for plant RNA samples, enabling scalable multiplexed RNA sequencing for plant research applications.
  • MERCURIUS™ FLASH-seq (Single-Cell) Kit Plate-based full-length single-cell RNA-seq kit delivering ultra-sensitive detection of rare cells with automation-friendly workflows, capturing up to 2x more genes than competing single-cell solutions.
  • DRUG-seq Service Fee-for-service extraction-free RNA-seq using MERCURIUS DRUG-seq chemistry for adherent and suspension cell lines, targeting screening, mechanism-of-action studies, and toxicity profiling at scale.
  • Total DRUG-seq Service Fee-for-service extraction-free total RNA-seq using MERCURIUS Total DRUG-seq for large-scale compound and toxicology screens requiring whole-transcriptome readouts.
  • Single-Cell FLASH-seq Service Fee-for-service plate-based full-length single-cell RNA-seq using MERCURIUS FLASH-seq for sorted or rare cells, delivering ultra-sensitive transcriptomes.
  • Spheroid DRUG-seq Service Fee-for-service extraction-free RNA-seq for 3D spheroid models capturing complex biology, mechanisms, and toxicity responses in physiologically relevant models.
  • BRB-seq Service Fee-for-service multiplexed bulk RNA-seq for purified RNA, ideal for cohorts, time-courses, and large gene expression profiling projects.
  • Total BRB-seq Service Fee-for-service total RNA BRB-seq capturing coding and non-coding transcripts for scalable whole-transcriptome studies on purified RNA samples.
  • Full-Length BRB-seq Service Fee-for-service full-length mRNA BRB-seq for isoform, splicing, and expression analyses across many purified RNA samples.
  • Low-Input FLASH-seq Service Fee-for-service full-length RNA-seq for scarce or precious low-input RNA providing high sensitivity from picogram to nanogram inputs.
  • High-Sensitivity BRB-seq Service Fee-for-service high-sensitivity BRB-seq for transcriptomics projects with limited input RNA starting from 100 pg per sample.
  • Total Blood BRB-seq Service Fee-for-service total RNA-seq from purified blood RNA for maximum detection of coding and non-coding transcripts.
  • Plant BRB-seq Service Fee-for-service BRB-seq tailored for plant RNA samples, enabling scalable multiplexed RNA sequencing for plant research.

Quantifiable outcome

  • Up to 384 samples pooled and processed in a single tube, reducing plastic consumable use by up to 95%
  • +5 more outcomes

Companies that use Alithea Genomics

Customer profile

Named customers20 records

Segments4 records

Ideal customer profiles3 records

Alithea Genomics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration1 record

AI capability3 records

Feature9 records

Alithea Genomics partnerships and signals

Strategic signal

Partnerships

Six partnerships are on record, tiered flagship / strategic, core / strategic and minor.

  • Revvity Inc.flagship / strategicChannel Partner/ Reseller/ Distributor · 8 June 2026Revvity Inc. serves as the global commercial distributor for MERCURIUS™ DRUG-seq and MERCURIUS™ Total DRUG-seq solutions. The distribution agreement leverages Revvity's comprehensive drug discovery and screening portfolio and global commercial network to broaden access to Alithea's transcriptomics technologies. The collaboration enables researchers to integrate transcriptomic profiling into Revvity's large-scale phenotypic and functional genomics workflows. Revvity had 2025 revenue of $2.9B with ~11,000 employees serving customers in 160+ countries.
  • SPT Labtechcore / strategicTechnology or Integration · 5 November 2025SPT Labtech and Alithea Genomics announced a collaboration to develop automation solutions for single-cell transcriptomics. The partnership integrates Alithea's MERCURIUS™ FLASH-seq and MERCURIUS™ Total DRUG-seq technologies with SPT Labtech's firefly® liquid handling platform for automated, scalable, and reproducible RNA-seq workflows. The companies released joint application notes and hosted a co-marketing webinar on November 10, 2025. This addresses the key bottleneck of manual library preparation in single-cell transcriptomics, improving reproducibility, throughput, and accessibility.
  • PamGene InternationalminorStrategic or Co-development Partner · 17 January 2023PamGene International is a partner in the MAINLINE consortium with Alithea Genomics and Lausanne University Hospital, awarded a €1M Eurostars grant to develop a pan-cancer blood test for predicting immune checkpoint inhibitor (ICI) therapy response. The project combines transcriptomics (Alithea's technology) and kinomic profiling (PamGene's technology) to create a multi-omics biomarker model validated in clinical settings.
  • Lausanne University Hospital (CHUV)minorStrategic or Co-development Partner · 17 January 2023Lausanne University Hospital (CHUV) is a partner in the MAINLINE consortium with Alithea Genomics and PamGene International, awarded a €1M Eurostars grant. CHUV contributes clinical expertise and validation capabilities for the pan-cancer blood test project, combining transcriptomic and kinomic biomarker profiles to predict ICI therapy response across multiple cancers.
  • Arctoriscore / strategicStrategic or Co-development PartnerArctoris partnered with Alithea Genomics for the 1536 DRUG-seq early access launch webinar (June 24, 2026). Arctoris contributes its Ulysses® automated platform for fully automated experimental execution in 1536-well format, including cell preparation, compound treatment, incubation, and sample preparation. The partnership demonstrates how automated workflows enable reproducible 1536-well transcriptomic screening and bridges technical feasibility with practical drug discovery application.
  • OASIS Consortium (Health and Environmental Sciences Institute / The Broad Institute)core / strategicStrategic or Co-development PartnerAlithea Genomics is a technology partner in the OASIS Consortium (Omics for Assessing Signatures for Integrated Safety), a global initiative launched in 2023 led by HESI Global and The Broad Institute with 60+ global partners. The consortium evaluates multi-omics technologies including transcriptomics, proteomics, and Cell Painting for predictive chemical safety assessment. Alithea provides MERCURIUS™ DRUG-seq as the transcriptomic technology platform. The consortium aims to build confidence in Next Generation Risk Assessment (NGRA) frameworks and reduce reliance on animal testing.

Scale indicators10 records

Recent moves7 records

Expansion highlights6 records

Alithea Genomics competitors and assessment

Company assessment

Direct peers

  • Lexogen: Lexogen offers a portfolio of RNA-seq library prep kits (QuantSeq, CORALL, SIRV spike-ins) targeting similar pharma/biotech and academic customers. It is the closest direct competitor in terms of product category (RNA-seq kits) and customer base (transcriptomics researchers).
  • 10x Genomics: 10x Genomics' Chromium single-cell RNA-seq platform competes directly with Alithea's FLASH-seq offering and serves overlapping pharma/biotech and academic customers. Both companies target the high-throughput transcriptomics market with differentiated single-cell workflows.
  • Parse Biosciences: Parse Biosciences offers Evercode single-cell RNA-seq kits that compete with FLASH-seq for fixed-cell and high-throughput single-cell applications. Both target pharma/biotech and academic researchers needing scalable, plate-based scRNA-seq.
  • Bio-Rad Laboratories: Bio-Rad's ddSEQ single-cell RNA-seq and Droplet Digital PCR products overlap with Alithea's FLASH-seq and BRB-seq offerings. Both serve drug discovery and translational research customers with high-throughput molecular biology tools.

Emerging players

  • Fluent BioSciences: Fluent BioSciences offers PIPseq single-cell RNA-seq technology targeting similar translational and pharma customers. It is a smaller emerging competitor in the plate-based single-cell space where Alithea's FLASH-seq also competes.
  • Element Biosciences: Element Biosciences' AVITI sequencer is compatible with Alithea's MERCURIUS kits and competes in the broader NGS ecosystem. While Element focuses on sequencing instruments rather than library prep, the two companies share an emerging-player positioning around democratizing NGS for pharma and academic customers.

Broad incumbents

  • Illumina: Illumina dominates the sequencing-instrument market and also sells its own library prep and bulk RNA-seq reagents (e.g., TruSeq, Illumina Stranded mRNA). Alithea's kits are compatible with Illumina sequencers but compete with Illumina's reagent catalog for the same pharma/biotech budget.
  • New England Biolabs: NEB offers a broad portfolio of RNA-seq library prep reagents (NEBNext) that compete with MERCURIUS kits across academic and translational customers. As a large, established enzyme/reagent vendor, NEB represents a broad incumbent alternative.
  • Takara Bio: Takara Bio provides NGS library prep kits (SMARTer, ThruPLEX) and single-cell reagents overlapping with Alithea's BRB-seq and FLASH-seq offerings. As a diversified Japanese life sciences tools provider, it is a comparable broad incumbent.
  • Revvity: Revvity is Alithea's global distribution partner and a major life sciences tools player (formerly PerkinElmer) serving pharma, biotech, and diagnostics customers. While now a commercial partner, Revvity also offers overlapping drug-discovery and screening products in adjacent categories.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

Alithea Genomics social profiles

Digital presence

Alithea Genomics compliance and trust

Trust signal

Compliance1 record

Alithea Genomics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Alithea Genomics leadership team

Management profile

Number of profiles

Profiles5 records

Alithea Genomics subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Alithea Genomics funding detail

Funding detail

Funding overview

Funding rounds8 records

Investors8 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Alithea Genomics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Alithea Genomics

What does Alithea Genomics do?

Alithea Genomics develops and commercializes the proprietary MERCURIUS™ platform of RNA sequencing kits and matched services for high-throughput, screening-scale transcriptomics. Its products use early plate-based sample barcoding and massively multiplexed library preparation (pooling up to 384, or up to 1,536, samples per tube) combined with extraction-free workflows to deliver 3′ mRNA, full-length, total RNA, and single-cell readouts for pharmaceutical, biotech, CRO, agritech, cosmetics, and academic customers.

Is Alithea Genomics a public or private company?

Alithea Genomics is a private company. It is classified as venture growth investor backed and is currently operating.

When was Alithea Genomics founded?

Alithea Genomics was founded in 2020. It employs 11 to 50 people.

Where is Alithea Genomics based?

Alithea Genomics is headquartered in Epalinges, Switzerland, in the Europe region.

How does Alithea Genomics make money?

Three revenue lines are on record. RNA-seq Kits Sales are the primary driver. The others are RNA-seq Services and proprietary Transcriptomic Data Assets.

Who are Alithea Genomics's main competitors?

Direct peers on record are Lexogen, 10x Genomics, Parse Biosciences and Bio-Rad Laboratories. Emerging players are Fluent BioSciences and Element Biosciences. Broad incumbents are Illumina, New England Biolabs, Takara Bio and Revvity.

Does Alithea Genomics have an API?

No public API is recorded for Alithea Genomics.

What industry is Alithea Genomics in?

Alithea Genomics's product category is Genomics Research Tools. Its primary akta.pro industry code is HLAGANAE, Transcriptomics & Gene Expression Profiling Services, with a secondary code of HLAGAJAD, Bioinformatics & Multi-omics Analysis Software. Its NAICS code is 541714 and its SIC code is 8071.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
GlobeNewswireSouth Korea Automated Liquid Handling System Market Report Published; Breaks Down Demand Across Drug Discovery, Genomic Research, and Clinical DiagnosticsResearchAndMarkets.com published a market report on the South Korea automated liquid handling system market, projecting growth from $23.5 million in 2025 to $51.0 million by 2036, representing a compound annual growth rate of 7.47%. This growth is driven by increasing demand for automation in biotechnology, pharmaceuticals, and clinical research sectors, particularly for drug discovery, personalized medicine, and genomic research applications. Recent industry developments include product launches and collaborations among companies such as Beckman Coulter Life Sciences, SPT Labtech, Alithea Genomics, and Agilent Technologies to expand automated liquid handling solutions in the region.Pulse 2.0Alithea Genomics: $8.9 Million Seed Round Closed To Scale RNA-Seq For Drug Screening And ToxicologyAlithea Genomics closed a CHF 6.9 million ($8.9 million) seed round to scale its RNA-Seq technology for drug screening and toxicology. The funds will accelerate commercialization of its 1536-well MERCURIUS DRUG-seq kits and support AI-driven data assets. Leadership changes include Frederik Decouttere as CEO and Riccardo Dainese as chief commercial officer.FoundersTodayAlithea Genomics raises CHF 6.9M Seed round to scale RNA sequencing for drug discoveryAlithea Genomics, a transcriptomics technology spinout from EPFL based in Lausanne, Switzerland, has completed a CHF 6.9 million seed funding round to scale commercialization of its RNA sequencing tools for drug discovery and biological research. The round was led by Genku Ventures with participation from Novalis Biotech, Zürcher Kantonalbank, and private investors, and includes an additional CHF 3 million in new funding beyond the initial target. The company also announced leadership changes, with Chairman Frederik Decouttere assuming the CEO role to focus on commercial expansion as the firm accelerates go-to-market efforts for its MERCURIUS DRUG-seq platform.Tech Funding NewsROXFIT lands £1.9M to build AI training platform for HYROX athletes — TFNSwiss biotech startup Alithea Genomics has closed a CHF 6.9 million ($8.9 million) seed funding round to scale its RNA sequencing technology and make large-scale transcriptomics more accessible for drug discovery and toxicology research. The round included an additional CHF 3 million led by Genku Ventures, with participation from Novalis Biotech, Zürcher Kantonalbank, and several private investors. Alongside the funding, the company announced leadership changes with Frederik Decouttere transitioning from Chairman to CEO and co-founder Riccardo Dainese moving from CEO to Chief Commercial Officer.BioSpaceAlithea Genomics Closes CHF 6.9 M Seed Round, Using Proceeds to Unlock Industrial-Scale RNA-seq for Primary Drug Screening and ToxicologyAlithea Genomics closed a CHF 6.9 million seed round with an additional CHF 3 million in funding led by Genku Ventures and joined by Novalis Biotech, Zürcher Kantonalbank, and private investors. The proceeds will accelerate commercialization of 1536-well MERCURIUSTM DRUG-seq kits for industrial-scale RNA sequencing in drug screening and toxicology applications, as well as fuel AI/ML initiatives with proprietary transcriptomic data assets. Concurrent with the funding, Frederik Decouttere was appointed CEO while co-founder Riccardo Dainese transitioned to Chief Commercial Officer.FinSMEsAlithea Genomics Closes USD8.9M Seed FundingAlithea Genomics, a Lausanne-based RNA sequencing and transcriptomics company, closed its seed financing round with an additional CHF 3 million ($3.9 million), bringing the total seed round to CHF 6.9 million ($8.9 million). The round was led by Genku Ventures and joined by Novalis Biotech and Zürcher Kantonalbank, alongside several private investors. In conjunction with the funding, Frederik Decouttere assumes the CEO role while Riccardo Dainese transitions to CCO, and the company plans to use the funds to accelerate commercialization of its 1536-well MERCURIUS DRUG-seq kits and develop proprietary transcriptomic data assets for AI/ML initiatives.VenturelabCHF 6.9M seed round for Alithea Genomics to advance large-scale RNA sequencingLausanne-based Alithea Genomics has secured CHF 6.9 million in seed financing, led by Genku Ventures with participation from Novalis Biotech, Zürcher Kantonalbank, and private investors, to accelerate commercialization of its high-throughput MERCURIUS™ DRUG-seq RNA sequencing kits for drug discovery and toxicology applications. Founded in 2020 as an EPFL spin-off, the company develops RNA-seq technologies enabling large-scale transcriptomic profiling at lower cost for early-stage pharmaceutical research. Concurrent with the round, Chairman Frederik Decouttere has assumed the CEO role as the company scales its commercial operations.MorningstarAlithea Genomics Closes CHF 6.9 M Seed Round, Using Proceeds to Unlock Industrial-Scale RNA-seq for Primary Drug Screening and ToxicologyAlithea Genomics closed its seed financing round totaling CHF 6.9 million ($8.9 million), with Genku Ventures leading and participation from Novalis Biotech, Zürcher Kantonalbank, and private investors. The funding will accelerate commercialization of MERCURIUS™ DRUG-seq kits enabling industrial-scale 1536-well RNA sequencing for primary drug screening and exploratory toxicology. Concurrent with the funding, Frederik Decouttere was appointed CEO, succeeding co-founder Riccardo Dainese who transitions to Chief Commercial Officer.startupticker.chAlithea Genomics closes CHF 6.9M round and names new CEOAlithea Genomics announced the closing of its expanded seed financing round totaling CHF 6.9 million ($8.9 million), with CHF 3 million added to the original round, led by Genku Ventures and joined by Novalis Biotech, Zürcher Kantonalbank, and private investors. The funding will accelerate commercialization of the company's 1536-well MERCURIUSTM DRUG-seq kits for large-scale RNA sequencing in drug discovery and toxicology applications. Concurrent with the funding, Frederik Decouttere, currently Chairman, assumes the CEO role while co-founder Riccardo Dainese transitions to Chief Commercial Officer.BioAlpsAlithea Genomics Closes CHF 6.9 M Seed RoundAlithea Genomics, a Biopôle-based RNA sequencing and transcriptomics company, announced the closing of an additional CHF 3 million seed funding round, bringing the total seed round to CHF 6.9 million ($8.9 million), with Genku Ventures leading and participation from Novalis Biotech, Zürcher Kantonalbank, and private investors. The proceeds will accelerate commercialization of its 1,536-well MERCURIUSTM DRUG-seq kits for cell transcriptomics in drug screening and toxicology, while also funding new technology development and proprietary transcriptomic data assets for AI/ML initiatives. Concurrent with the funding, Frederik Decouttere assumed the CEO role from co-founder Riccardo Dainese, who transitioned to Chief Commercial Officer.